Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG for Digital Nerve Laceration
NCT04270019Phase 2Withdrawn
- Sponsor
- Nova Scotia Health
- Start
- Jun 2020
- Primary completion
- Sep 2023
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Biodegradable Polymers
01
Overview
Phase 2, randomised, double-blind trial of polyethylene glycol 3350 in digital nerve laceration (2 arms), sponsored by Nova Scotia Health. Primary endpoint: Change in Sensory Recovery at 6 months. Planned start Jun 2020; status: withdrawn.
02
Drugs
polyethylene glycol 3350
03
Conditions
digital nerve laceration
Beyond the preview
Go deeper on NCT04270019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270019.